BHIC BioScience Health Innovations, Inc.
Services-Computer Processing & Data Preparation · OTC · SEC CIK 1784440 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.4%
TTM net income YoY-190.2%
TTM EPS YoY-187.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin54.4%
Operating margin-17.4%
Net margin-18.4%
FCF margin—
EBITDA margin—
Returns
ROE-34.5%
ROA-30.3%
ROIC (approx.)-66.0%
Asset turnover1.64x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.69x
Accruals ratio20.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $970,071 | $1.04M | $750,946 | $1.57M | $1.13M | $1.76M | $1.23M | $610,222 |
| Cost of revenue | $332,507 | $376,881 | $265,350 | $1.00M | $433,196 | $682,985 | $330,925 | $271,213 |
| Gross profit | $637,564 | $659,483 | $485,596 | $571,863 | $698,231 | $1.07M | $896,145 | $339,009 |
| R&D expense | $59,541 | $70,584 | $49,722 | $94,981 | $19,589 | $9,243 | $37,540 | -$3,900 |
| SG&A expense | $720,121 | $804,136 | $625,809 | $656,204 | $576,656 | $540,074 | $433,561 | $300,174 |
| Operating income | -$148,260 | -$217,882 | -$229,907 | -$156,669 | -$8,782 | $457,704 | $426,798 | $9,957 |
| Interest expense | $965 | — | — | — | $0 | — | — | — |
| Income tax | $0 | -$32,129 | — | $76,961 | $0 | $0 | — | $0 |
| Net income | -$149,225 | -$185,753 | -$229,907 | -$233,630 | -$8,782 | $457,704 | $426,798 | $9,957 |
| EPS (basic) | -0.01 | -0.02 | -0.02 | — | 0.00 | 0.04 | 0.01 | — |
| EPS (diluted) | -0.01 | -0.02 | -0.02 | — | 0.00 | 0.04 | 0.01 | — |
| Weighted avg. shares (diluted) | 11.84M | 11.68M | 11.38M | — | 10.98M | 11.40M | 44.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.69M | $712,378 | $1.15M | $661,925 | $1.14M | $1.30M | $1.03M | $662,517 |
| Receivables | $478,083 | $396,899 | $78,278 | $399,257 | $63,212 | $390,013 | $93,449 | $100,285 |
| Inventory | $711,269 | $797,183 | $874,340 | $336,348 | $757,500 | $248,519 | $215,696 | $58,319 |
| Current assets | $3.01M | $1.99M | $2.19M | $1.56M | $1.99M | $1.99M | $1.34M | $847,751 |
| Intangibles | $170,307 | $109,845 | $82,887 | $82,887 | $72,101 | $72,101 | $56,037 | $26,037 |
| Total assets | $3.20M | $2.14M | $2.33M | $1.71M | $2.07M | $2.06M | $1.39M | $873,788 |
| Total liabilities | $281,516 | $301,209 | $645,749 | $229,851 | $356,140 | $337,632 | $132,921 | $38,548 |
| Shareholders' equity | $2.92M | $1.83M | $1.68M | $1.48M | $1.71M | $1.72M | $1.26M | $835,240 |
| Shares outstanding | 12.03M | 11.75M | 10.98M | 10.98M | 10.98M | 43.92M | 43.92M | 10.98M |
| Cash flow statement | ||||||||
| Operating cash flow | -$150,826 | -$541,874 | -$552,107 | -$100,696 | -$340,445 | $285,010 | $328,309 | -$50,305 |
| Investing cash flow | -$60,462 | -$26,958 | $0 | -$10,786 | $0 | -$16,064 | -$30,000 | -$19,000 |
| Financing cash flow | $1.19M | $136,205 | $1.04M | -$366,016 | $180,461 | $2,119 | $67,516 | $398,602 |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.